2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices
Cardiometabolic Health Congress
JULY 17, 2024
Notes: Approved after initial rejection two years prior based on safety data from Japan, where the drug had been used since 2020 It can only be used in kidney disease patients on dialysis for at least 3 months. The label includes a “black box” warning for CV risk due to blood clots.
Let's personalize your content